XIE, SINING
XIE, SINING
Mostra
records
Risultati 1 - 5 di 5 (tempo di esecuzione: 0.003 secondi).
Operational Definitions of Polypharmacy and Their Association with All-Cause Hospitalization Risk: A Conceptual Framework Using Administrative Databases
2025 S. Scotti, L. Scotti, F. Galimberti, S. Xie, M. Casula, E. Olmastroni
USE OF MULTIPLE ANALYTIC APPROACHES TO IDENTIFY NEW MARKERS/RISK FACTORS FOR CARDIOVASCULAR DISEASES AND EVALUATE THEIR ROLE AS POSSIBLE PHARMACOLOGICAL TARGETS
2024 S. Xie
Ezetimibe: Integrating Established Use with New Evidence - A Comprehensive Review
2024 E. Olmastroni, S. Scotti, F. Galimberti, S. Xie, M. Casula
Effect of lipid-lowering therapies on C-reactive protein levels: a comprehensive meta-analysis of randomized controlled trials
2024 S. Xie, F. Galimberti, E. Olmastroni, T.F. Luscher, S. Carugo, A.L. Catapano, M. Casula, C. Wanner, S. Yusuf, A. Maggioni, A. Kirby, H. Ogawa, E.K. Hoogeveen, I. Seljeflot, K. Welty, M. Benderly, J.E. Manson, K. Wolski, C.P. Cannon, F.J. Raal, D. Kallend, J. Foody, M. Louie
HDL in atherosclerotic cardiovascular disease : In search of a role
2021 M. Casula, O. Colpani, S. Xie, A.L. Catapano, A. Baragetti